(0.06%) 5 472.30 points
(0.10%) 39 150 points
(0.37%) 17 783 points
(0.04%) $80.86
(-3.66%) $2.66
(-0.81%) $2 311.90
(0.16%) $28.92
(3.51%) $1 021.00
(0.27%) $0.936
(0.69%) $10.68
(0.43%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer...
Stats | |
---|---|
今日成交量 | 1.25M |
平均成交量 | 126 338 |
市值 | 20.90M |
EPS | $-0.240 ( Q1 | 2024-05-15 ) |
下一个收益日期 | ( $0 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.037 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0140 (1.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Guerin Mark Patrick | Buy | 8 666 | Common Stock |
2024-03-14 | Guerin Mark Patrick | Sell | 2 591 | Common Stock |
2024-03-13 | Guerin Mark Patrick | Sell | 8 666 | Restricted Stock Units |
2024-03-13 | Fruchtman Steven M | Buy | 23 111 | Common Stock |
2024-03-14 | Fruchtman Steven M | Sell | 8 727 | Common Stock |
INSIDER POWER |
---|
74.31 |
Last 95 transactions |
Buy: 2 889 396 | Sell: 191 603 |
音量 相关性
Onconova Therapeutics Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Onconova Therapeutics Inc 相关性 - 货币/商品
Onconova Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $226 000 |
毛利润: | $226.00B (100 000 000.00 %) |
EPS: | $-0.900 |
FY | 2023 |
营收: | $226 000 |
毛利润: | $226.00B (100 000 000.00 %) |
EPS: | $-0.900 |
FY | 2022 |
营收: | $226 000 |
毛利润: | $212 000 (93.81 %) |
EPS: | $-0.880 |
FY | 2021 |
营收: | $226 000 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.960 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Onconova Therapeutics Inc
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。